Compare Johnson & Johnson (JNJ) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Johnson & Johnson trades at $249.45 (market cap $598.96B), while Direxion Daily TSLA Bull 2X Shares trades at $11.31. The key difference: Johnson & Johnson pays a 2.15% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Johnson & Johnson is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| JNJ | TSLL | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $23.03 |
52-Week Low | $164.36 | $10.29 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
TSLL is trading at $10.72, down 5.84% with a bearish technical outlook. The stock faces selling pressure with moving averages indicating a downtrend and key resistance at $12. Recent news highlights upcoming Tesla earnings as a potential catalyst, though financial ratios remain unavailable for fundamental assessment.
The stock's outlook is cautious due to technical weakness and lack of current financial data. Investment opportunity hinges on Tesla's upcoming earnings report, while risks include sustained bearish momentum and dependency on Tesla's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
